Korea Exchange · Healthcare
Hanmi Pharm. stock from India: price, numbers and tax
Hanmi Pharm. (128940) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Hanmi Pharm. at a glance
- Price
- ₩480,500.00-₩53,500.00 (10.02%)
- Market cap
- ₩6.09T
- Day range
- ₩475,000.00 – ₩526,000.00
- P/E
- 25.95
- Dividend yield
- 0.42%
- Volume
- 295.86K
- 1 month
- -2.83%
- 6 months
- -1.33%
- YTD
- +6.31%
- 1 year
- +35.54%
- 5 years
- +95.74%
Hanmi Pharm. statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩1.5T | ₩1.5T | ₩1.5T | ₩1.3T | ₩1.2T |
| Gross profit | ₩884.4B | ₩817.0B | ₩829.2B | ₩718.6B | ₩632.8B |
| Operating income | ₩223.9B | ₩216.2B | ₩224.9B | ₩158.1B | ₩125.4B |
| Net income | ₩170.5B | ₩121.3B | ₩146.2B | ₩82.8B | ₩67.0B |
| Earnings per share | ₩13,371.00 | ₩9,567.28 | ₩11,522.00 | ₩6,517.20 | ₩5,269.74 |
| EBITDA | ₩322.7B | ₩293.0B | ₩323.3B | ₩249.0B | ₩209.4B |
| Total assets | ₩2.2T | ₩2.0T | ₩1.9T | ₩1.9T | ₩1.9T |
| Total debt | ₩434.2B | ₩496.7B | ₩572.9B | ₩678.3B | ₩756.3B |
| Cash and short-term investments | ₩200.7B | ₩193.2B | ₩254.2B | ₩236.7B | ₩211.7B |
| Shareholders' equity | ₩1.2T | ₩1.1T | ₩955.4B | ₩871.9B | ₩802.9B |
| Operating cash flow | ₩170.1B | ₩193.5B | ₩216.5B | ₩162.3B | ₩201.9B |
| Free cash flow | ₩127.1B | ₩130.9B | ₩172.8B | ₩112.7B | ₩167.5B |
| Capital expenditure | −₩43.0B | −₩62.6B | −₩43.7B | −₩49.6B | −₩34.4B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Hanall Biopharma | 009420.KS | ₩44,000.00 | ₩2.24T |
| Celltrion Pharm | 068760.KQ | ₩38,800.00 | ₩1.72T |
| Daewoong pharmaceutical | 069620.KS | ₩108,500.00 | ₩1.25T |
| JW Pharmaceutical | 001060.KS | ₩26,350.00 | ₩608.52B |
| HLB Pharmaceutical | 047920.KQ | ₩13,130.00 | ₩430.65B |
| EuBiologics | 206650.KQ | ₩8,420.00 | ₩309.21B |
| Korea United Pharm | 033270.KS | ₩17,860.00 | ₩257.93B |
| Whan In Pharm | 016580.KS | ₩10,180.00 | ₩188.17B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Hanmi Pharm. from India
What Hanmi Pharm. does
A globally active pharmaceutical company, Hanmi Pharm. Co., Ltd. was established in Seoul, South Korea, in 1973. Hanmi Pharm. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Hanmi Pharm. shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.